Please login to the form below

Not currently logged in
Email:
Password:

Warner Chilcott

This page shows the latest Warner Chilcott news and features for those working in and with pharma, biotech and healthcare.

US tax changes claim Pfizer scalp as Allergan deal abandoned

US tax changes claim Pfizer scalp as Allergan deal abandoned

So for Allergan - formerly known as Actavis, its acquisitions of Warner Chilcott in 2013, Forest Laboratories in 2014 and Allergan in 2015 that turned it into a $109bn company would be

Latest news

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2014 Pharma deals during September 2014

    Virgin Media. UK. 2013. Actavis. Warner Chilcott. Ireland. 2013. Perrigo. Elan.

  • Pharma deals during April 2014 Pharma deals during April 2014

    This is the latest of the Actavis buying binge frenzy adding to the acquisition of Warner Chilcott last year and Forest Laboratories last month.

  • Pharma deals during March 2014 Pharma deals during March 2014

    This follows on from several other acquisitions of Irish entities, which result in US companies paying Irish corporation tax, eg the acquisition by Perrigo of Elan and Actavis' acquisition of Warner ... Chilcott last year.

  • Pharma deals during February 2014 Pharma deals during February 2014

    This deal comes hot on the heels of the acquisition of Warner Chilcott in 2013 and Watson Pharmaceuticals' acquisition of Actavis back in 2012.

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    Bausch &Lomb/ Valeant. Company acquisition. Ophthalmology business. 8, 700. Warner Chilcott/ Actavis.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics